How to Accelerate Adoption and Lower TCO With a Configurable RTSM System

Configurable RTSM systems present new opportunities to accelerate adoption of clinical trial platforms, while lowering the total cost of ownership. Reduce build times, gain inventory oversight, and implement mid-study changes for the simplest to the most complex studies without the need for programming or coding, which eliminates the need for prolonged user acceptance testing.

Register Free: https://www.pharmexec.com/pe/rts_system

Event Overview:

Configurable RTSM systems present new opportunities to accelerate adoption of clinical trial platforms, while lowering the total cost of ownership. As the industry continues to move away from cumbersome custom solutions, new questions arise about how to standardize approaches to RTSM ownership, manage platform adoption, conduct site and sponsor training, perform cross-study analytics and reporting, and achieve economies of scale.

Key Learning Objectives:

• Learn how NeoTX is making new discoveries in cancer therapy.
• Learn how a configurable RTSM system plays a crucial role in their clinical trial operations.
• Learn how NeoTX is using data to drive organizational decision-making.
• Learn how configurable RTSM solutions allow for standardization via
  • Validated approaches
  • Site and sponsor training
  • Help documentation and support

Who Should Attend:

• Sponsor and CRO roles who are responsible for:
  • Clinical development planning
  • Study designs
  • Clinical data management, collecting and evaluating trial metrics
• Project management of studies, process optimization, and operational excellence

Speakers

Asher Nathan
CEO, Director
NeoTX

Asher Nathan has extensive experience in diverse roles within the industry, including serving as founder, entrepreneur and investor, and has authored over 25 patents in the field of biotechnology. Before NeoTX, he founded IntelliGene and EvoRx, two biotech companies formed around technologies he invented. EvoRx was established together with Nobel Prize Winners Arthur Kornberg and Roger Kornberg. Asher was also a Managing Director at Paramount Biocapital, a drug development and healthcare investment firm that created over 40 start-up companies, before he co-founded Zoticon Bioventures, where he served as Managing Director.

Dror Graiver
Clinical Trial Manager
NeoTX

Dror is a Clinical Trial Manager at NeoTX Therapeutics. Dror holds a B.Sc. of Biology from Ben-Gurion University and a M.Sc. in Medical Sciences from Tel-Aviv University. Dror majored in drug development and implementation. In addition to working as a Clinical Trial Manager, Dror has spent time as a CRA at Karyopharm and PPD, respectively. Dror has held responsibility for the management of clinical databases, and has managed, supervised and supported multiple international clinical trials in several therapeutic fields (ie, oncology, neurology, infectious diseases, etc.).

Ryan Kennedy
Global VP, Product Strategy, Experience, and Enablement
Oracle

Ryan Kennedy is the Global VP of Product Strategy, Experience, and Enablement for Oracle Health and AI. Ryan has 22 years of clinical research experience, with roles ranging from direct site and patient management at University of Pittsburgh’s Cancer Center to working in the field of eCOA and eClinical technology development. He has a bachelor’s in Philosophy and Neuroscience from Allegheny College and a MBA from the Katz School of Business, University of Pittsburgh.

Sean Roy
Senior Consulting Practice Director
Oracle

Sean Roy is the Senior Director of North America Services for Oracle’s Health Sciences Global Business Unit. Sean has 10 years of IRT/RTSM domain expertise and 14+ years in the services delivery of clinical trial software. Sean holds a BS in Management from Bentley University, a MS in Leadership from Northeastern University, and a Ph.D. in Organizational Leadership from Indiana Wesleyan University.

Register Free: https://www.pharmexec.com/pe/rts_system